This article is the second in the Investigator Spotlight Series that was the brain child of Dr. Dawn Hayward, a NCI Communications Fellow at OCCPR, highlighting our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientists Dr. David Fenyö and researcher Emily Kawaler!

Online on July 24th on Cell Systems, Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers shared the results of their first-ever, crowd-sourced NCI-CPTAC DREAM Proteogenomic Challenge. In this community-based, collaborative contest participants developed computational algorithms to predict protein abundance and phosphoprotein levels.

Focusing on the Issues

A major goal for NCI’s Cancer Proteomic Tumor Analysis Consortium (CPTAC) is to translate proteomic technologies into clinical use to improve treatment and diagnosis of cancer. Dr. Amanda Paulovich and team from the Fred Hutchinson Cancer Research Center (members of the CPTAC Consortium) have achieved an important milestone in this regard, by establishing a Clinical Laboratory Improvement Amendments (CLIA) - certified laboratory for running targeted proteomic assays based on multiple reaction monitoring (MRM) mass spectrometry (MS).

Two new studies released July 9^th, 2020 in Cell unravel the biology of lung adenocarcinoma (LUAD) using a suite of molecular techniques that, combined, provide a more complete picture of the disease than ever before. Using a diverse cohort of smokers and non-smokers, male and female, from around the world, researchers from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the International Cancer Proteogenome Consortium (ICPC) draw out a clearer understanding of LUAD tumor progression, identify biomarkers, and propose alternative therapeutic targets.

Join Dr. Alexey Nesvizhskii, Professor of Pathology and Computational Medicine & Bioinformatics at University of Michigan, as he speaks on our next OCCPR Webinar about his ultrafast MSFragger software. The webinar will take place on Wednesday, July 15th at 1pm - registration is free, but required.

The Investigator Spotlight Series was the brain child of Dr. Dawn Hayward, an NCI Communications Fellow at OCCPR, to highlight our CPTAC researchers and thier work. In case you missed it the first time, here she features CPTAC scientist Dr. Karin Rodland. Enjoy!

We are so excited to be a part of the AACR Virtual Meeting II, June 22-24, 2020! Join us for our Clinical Proteomic Tumor Analysis Consortium (CPTAC) Educational Session: Resources and Data Dissemination Tuesday June 23rd, 3:00-5:00 p.m.

In a new study published in Analytical Chemistry, we see another example of ingenuity by NCI’s Office of Cancer Clinical Proteomic Research (OCCPR) Clinical Proteomic Tumor Analysis Consortium (CPTAC) scientists. In an effort to optimize analytical output and conserve hard-to-obtain biospecimen samples, CPTAC researchers out of John Hopkins School of Medicine developed a new integrated workflow for multiplex analysis of global, glyco-, and phospho-proteomics. 

108 cases of the NCI’s Clinical Proteomic Tumor Analysis Program (CPTAC) Head and Neck Squamous Cell Carcinoma Discovery Study have been proteomically and genomically profiled! Each case includes HPV-negative, treatment naive and normal adjacent tissue, and includes proteomic ad phosphoproteomic data on the Proteomic Data Commons (PDC), as well as RNA-Seq, miRNA-Seq, WGS, WXS genomic data on the Genomic Data Commons (GDC).   

50 new pathology slides from 33 new Acute Myeloid Leukemia (AML) subjects are now available on the TCIA-CPTAC Pathology Portal. The April 2020 image release brings the total number of AML pathology slides to 120 from 88 subjects, with most of them also having both tumor blood and marrow imaging.